Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy

Journal of Immunotherapy

Volumn 26, Issue 3, 2003, Pages 241-256

  Sili, Uluhan ^a   Huls, M Helen ^a   Davis, Alan R ^a   Gottschalk, Stephen ^a   Brenner, Malcolm K ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

CTL; Dendritic cell; Human; Transplantation; Viral

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOBLASTOID CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

CELL LINE; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 0037500890     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200305000-00008     Document Type: Article

References (41)

1. Greenberg PD, Riddell SR. Deficient cellular immunity-finding and fixing the defects. Science. 1999; 285:546-551.
2. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995; 345:9-13.
3. Zaia JA, Sissons JG, Riddell S, et al. Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology (Am Soc Hematol Educ Program). 2000:339-355.
4. Rooney CM, Aguilar LK, Huls MH, et al. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-229.
5. Rochford R, Cannon MJ, Sabbe RE, et al. Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol. 1997; 10:183-195.
6. Oldstone MB. How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Virology. 1997; 234:179-185.
7. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother. 2000; 45(suppl T3):35-43.
8. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol. 1998; 10:444-449.
9. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods. 2001; 258:111-126.
10. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000; 192:1637-1644.
11. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002; 99:4357-4363.
12. Peggs KS, Mackinnon S. Clinical trials with CMV-specific T cells. Cytotherapy. 2002; 4:21-28.
13. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002; 99:3916-3922.
14. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333:1038-1044.
15. Keever-Taylor CA, Margolis D, Konings S, et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant. 2001; 7:247-256.
16. Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001; 8:930-937.
17. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001; 411:380-384.
18. Smith CA, Ng CY, Loftin SK, et al. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996; 23:213-220.
19. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992; 176:157-168.
20. Davis AR, Meyers K, Wilson JM. High throughput method for creating and screening recombinant adenoviruses. Gene Ther. 1998; 5:1148-1152.
21. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol. 2000; 74:10274-10286.
22. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T- cell receptor usage of pp65-specific CTL. J Virol. 1996; 70:7569-7579.
23. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999; 223:1-15.
24. Yang J, Lemas VM, Flinn IW, et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood. 2000; 95:241-248.
25. Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol. 2000; 165:1182-1190.
26. Engstrand M, Tournay C, Peyrat MA, et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation. 2000; 69:2243-2250.
27. Singhal S, Shaw JC, Ainsworth J, et al. Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation. 2000; 69:2251-2259.
28. Garlie NK, LeFever AV, Siebenlist RE, et al. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother. 1999; 22:336-345.
29. van Rhee F, Barrett J. Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation. Cytotherapy. 2002; 4:3-10.
30. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168:909-18.
31. Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996; 87:2594-2603.
32. Gallot G, Vivien R, Ibisch C, et al. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. J Immunol. 2001; 167:4196-4206.
33. Keenan RD, Ainsworth J, Khan N, et al. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol. 2001; 115:428-434.
34. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001; 98:505-512.
35. Rufer N, Migliaccio M, Antonchuk J, et al. Transfer of the human telomerase reverse transcription (TERT) gene into T lymphocytes results in extension of replicative potential. Blood. 2001; 98:597-603.
36. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood. 1999; 94:3242-3250.
37. Sun Q, Burton RL, Dai LJ, et al. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol. 2000; 165:4105-4111.
38. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol. 2000; 74:2567-2583.
39. Rea D, Havenga MJ, van Den AM, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol. 2001; 166:5236-5244.
40. Ronchese F, Hermans IF. Killing of dendritic cells: a life cut short or a purposeful death? J Exp Med. 2001; 194:F23-F26.
41. Medema JP, Schuurhuis DH, Rea D, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med. 2001; 194:657-667.